
A new weight loss jab is set to be approved for use in the UK for patients with conditions such as diabetes or heart disease.
Tirzepatide, manufactured by Eli Lilly, can help patients lose an average of two-and-a-half stone, according to medical trials, and could be offered to up to 12 million people on the NHS to help tackle obesity.